Arcturus Therapeutics Holdings Inc. (ARCT): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of ARCT were reported in the last 12 months. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Arcturus Therapeutics
From the latest filingsOverall: more buying than selling. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns ARCT
134 funds and institutions reported ARCT shares worth $169M at the end of Q2 2026, about 89% of the company. The largest holder is Federated Hermes, Inc. with 11.6%.
Funds and institutions (13F) 89%Everyone else 11%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Federated Hermes, Inc. | 3.30M | 11.62% | $22.2M | No change |
| ARK Investment Management LLC | 2.90M | 10.21% | $19.5M | +5% |
| BlackRock, Inc. | 2.61M | 9.20% | $17.6M | No change |
| Sumitomo Mitsui Trust Group, Inc. | 1.96M | 6.91% | $13.2M | -14% |
| Amova Asset Management Americas, Inc. | 1.96M | 6.90% | $13.1M | -14% |
| Vanguard Capital Management LLC | 1.11M | 3.92% | $7.5M | +1% |
| Two Sigma Investments, LP | 1.09M | 3.84% | $7.3M | +1% |
| Vanguard Portfolio Management LLC | 951,575 | 3.35% | $6.4M | -3% |
| Geode Capital Management, LLC | 693,660 | 2.44% | $4.7M | +5% |
| AQR Capital Management LLC | 675,014 | 2.37% | $4.5M | +319% |
| Jacobs Levy Equity Management, Inc | 647,511 | 2.28% | $4.4M | +226% |
| State Street Corp | 569,598 | 2.00% | $3.8M | +5% |
| UBS Group AG | 490,632 | 1.73% | $3.3M | +7% |
| D. E. Shaw & Co., Inc. | 392,358 | 1.38% | $2.6M | +56% |
| Empire Life Investments Inc. | 366,217 | 1.29% | $2.5M | -5% |
| Hennion & Walsh Asset Management, Inc. | 346,207 | 1.22% | $2.3M | +24% |
| Millennium Management LLC | 336,996 | 1.19% | $2.3M | -30% |
| Goldman Sachs Group Inc | 309,863 | 1.09% | $2.1M | +56% |
| BNP Paribas Financial Markets | 261,789 | 0.92% | $1.8M | +34% |
| Charles Schwab Investment Management Inc | 231,628 | 0.81% | $1.6M | +7% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
No ARCT insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
ARCT short interest
High short interest. 19.0% of ARCT shares are sold short: about 1 share in 5. Over the last 12 reports the number of shares short went down 18%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 5.41M ARCT shares were sold short, 19.0% of the shares outstanding, down 0.9% from the report before. At the average daily volume of 734,287 shares, buying them all back would take about 7.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 5.41M | 19.03% | -1% | 734,287 | 7.4 |
| Oct 15, 2026 | 5.46M | 19.21% | +2% | 653,118 | 8.4 |
| Sep 30, 2026 | 5.38M | 18.92% | -2% | 906,911 | 5.9 |
| Sep 15, 2026 | 5.47M | 19.24% | -10% | 858,221 | 6.4 |
| Aug 31, 2026 | 6.10M | 21.45% | -7% | 1.99M | 3.1 |
| Aug 14, 2026 | 6.53M | 22.96% | -9% | 661,601 | 9.9 |
| Jul 31, 2026 | 7.21M | 25.36% | +3% | 436,372 | 16.5 |
| Jul 15, 2026 | 7.00M | 24.64% | +3% | 654,282 | 10.7 |
| Jun 30, 2026 | 6.80M | 23.93% | +1% | 439,741 | 15.5 |
| Jun 15, 2026 | 6.71M | 23.60% | -0% | 378,532 | 17.7 |
| May 29, 2026 | 6.73M | 23.67% | +2% | 410,680 | 16.4 |
| May 15, 2026 | 6.57M | 23.13% | +2% | 495,602 | 13.3 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Arcturus Therapeutics company events
Arcturus Therapeutics filed 9 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Sep 23, 2026AnnouncementShared information with investors. Filing
- Aug 25, 2026AnnouncementShared information with investors. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 2, 2026AgreementArcturus Therapeutics, Inc., a wholly-owned subsidiary of Arcturus Therapeutics Holdings Inc., a Delaware corporation, entered into a series of agreements with Thermo Fisher Scientific Inc. and certain of Thermo Fisher’s affiliates to establish a strategic collaboration for the provision of… Filing
- Jun 5, 2026VoteReported shareholder vote results. Filing
- May 7, 2026LeadershipDennis Mulroy, 71, was appointed Chief Financial Officer of the Company. Filing
- Mar 3, 2026ResultsReleased financial results. Filing
- Dec 15, 2025LeadershipArcturus Therapeutics Holdings, Inc., a Delaware corporation and Andy Sassine, Chief Financial Officer of the Company and a member of the Company’s Board of Directors, mutually agreed to end their employment relationship in an amicable manner effective December 31, 2025. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Arcturus Therapeutics financials
Famous investors that hold ARCT
4 of the 50 well-known investors we track reported holding ARCT in their latest 13F filing. The largest position is Cathie Wood's, worth $41M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Cathie Wood · ARK Investment Management | Q3 2026 | 2.99M | $41M | 0.2% | +3% |
| Israel Englander · Millennium Management | Q3 2026 | 392,272 | $5.4M | 0.0% | +16% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 62,500 | $856K | 0.0% | +192% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 24,555 | $336K | 0.0% | -89% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named ARCT in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | Amova Asset Management Americas, Inc. | 13G/A | 5.9% |
| Nov 13, 2026 | Amova Asset Management Americas, Inc. | 13G/A | 5.9% |
| Oct 29, 2026 | Sumitomo Mitsui Trust Group, Inc. | 13G/A | 5.9% |
| Oct 29, 2026 | Sumitomo Mitsui Trust Group, Inc. | 13G/A | 5.9% |
| Oct 7, 2026 | Federated Hermes, Inc. | 13G/A | 5.9% |
| Oct 7, 2026 | Federated Hermes, Inc. | 13G/A | 5.9% |
Questions about Arcturus Therapeutics Holdings Inc. (ARCT) stock
Who owns the most ARCT stock?
The largest reported owner of Arcturus Therapeutics Holdings Inc. (ARCT) is Federated Hermes, Inc., with 11.6% of the company. In total, 134 funds and institutions reported holding ARCT at the end of Q2 2026, together about 89% of the shares. See the largest owners.
Are ARCT insiders buying or selling?
No ARCT insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in ARCT?
As of Oct 30, 2026, 5.41M ARCT shares were sold short, 19.0% of the shares outstanding, down 0.9% from the report before. At the average daily volume of 734,287 shares, buying them all back would take about 7.4 trading days (days to cover). See the history.
Which famous investors hold ARCT?
4 of the 50 well-known investors we track reported ARCT in their latest 13F filing, including Cathie Wood, Israel Englander, Jim Simons. The largest position is worth $41M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.